Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program – BioSpace

7th February 2019

Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program BioSpace

Published: Feb 06, 2019. – Iomab-ACT program intended to displace non-specific chemotherapy with targeted, single-dose, outpatient conditioning to improve …